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Abstract: Pulmonary dysfunction is among the most frequent complications to cardiac surgeries.
Exposure of blood to the cardiopulmonary bypass (CPB) circuit with subsequent lung
ischemia-reperfusion leads to the production of inflammatory mediators and increases in
microvascular permeability. The study aimed to elucidate histological, cellular, and metabolite changes
following two lung protective regimens during CPB with Histidine-Tryptophan-Ketoglutarate (HTK)
enriched or warm oxygenated blood pulmonary perfusion compared to standard regimen with no
pulmonary perfusion. A total of 90 patients undergoing CPB were randomized to receiving HTK,
oxygenated blood or standard regimen. Of these, bronchoalveolar lavage fluid (BALF) and lung tissue
biopsies were obtained before and after CPB from 47 and 25 patients, respectively. Histopathological
scores, BALF cell counts and metabolite screening were assessed. Multivariate and univariate analyses
were performed. Profound histological, cellular, and metabolic changes were identified in all patients
after CPB. Histological and cellular changes were similar in the three groups; however, some metabolite
profiles were different in the HTK patients. While all patients presented an increase in inflammatory
cells, metabolic acidosis, protease activity and oxidative stress, HTK patients seemed to be protected
against severe acidosis, excessive fatty acid oxidation, and inflammation during ischemia-reperfusion.
Additional studies are needed to confirm these findings.
Keywords: ischemia-reperfusion injury; CPB; lung protection; HTK; oxygenated blood; lung biopsy;
bronchoalveolar lavage; inflammation; metabolites; NMR
1. Introduction
Postoperative pulmonary dysfunction is the most common complication to cardiac surgeries
with the use of cardiopulmonary bypass (CPB), leading to prolonged hospitalization, increased
morbidity, and mortality [1]. The reasons are multifactorial and primarily related to impairments
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in gas exchange [2]. The main triggers are the CPB circuit with the patients’ blood being exposed
to a wide range of synthetic materials which induces a systemic inflammatory reaction and the
ischemia-reperfusion injury following weaning from CPB [3,4]. This can lead to postoperative bleeding,
infection, and multiple organ dysfunction syndromes (MODs), including acute lung injury and its
more severe form, acute respiratory distress syndrome (ARDS) [5–8]. Alveolar and endothelial damage
resulting in formation of pulmonary edema, accumulation of alveolar protein [9,10], and facilitation
of inflammatory cell sequestration have previously been confirmed in lung tissue biopsies and
bronchoalveolar lavage fluid (BALF) [11]. The consequence is a thickened alveolar-endothelial barrier
with compromised gas exchange between alveoli and the blood [12].
We have previous demonstrated that CPB significantly impact the levels of blood metabolites
with fatty acids, phospholipids, ketones, and several amino acids were predictive of the degree of lung
tissue injury commonly observed on the second to third postoperative day [13,14]. Although these
studies provided insight into the systemic changes occurring during progression to lung injury after
CPB, there is still a need for knowledge regarding the pulmonary molecular changes during surgery.
Increasing evidence indicates that lung tissue protection by pulmonary artery perfusion with
blood [15–21] or a preservation solution [22–25] such as hypothermic histidine-tryptophan-ketoglutarate
(HTK [24–26]) during CPB may attenuate postoperative hypoxemia by supplying metabolic substrates
to the lung tissue exposed to re-perfusion [27]. Hypothermic HTK is used as a multi-organ preservation
solution for organ transplantation, including the lungs [25,28–30], in addition to its use as a cardioplegia
solution. Its buffer system is thought to withdraw extracellular sodium and calcium, together with
buffering of the extracellular space by means of histidine and histidine-hydrochloride, thus prolonging
the period during which organs tolerates interruption in blood supply [31]. It has been found that HTK
solution attenuated pulmonary edema until 12 h post-perfusion when compared to both saline and the
low-potassium dextran preservation solution in an experimental rat model of ex vivo lung perfusion [32].
In the randomized Pulmonary Protection Trial of adult patients undergoing elective cardiac surgery [26],
we found that postoperative arterial oxygenation on the first postoperative day was slightly better
following pulmonary artery perfusion with normothermic oxygenated blood during CPB compared to
pulmonary artery perfusion with hypothermic HTK solution and standard regimen with no perfusion.
However, the baseline arterial oxygenation was higher in the patients receiving oxygenated compared
to the two other groups. The main aim of this study is to elucidate the pathophysiological changes
within lungs in more details in the three groups of patients included in the Pulmonary Protection Trial.
BALF and lung biopsies were collected from patients included in The Pulmonary Protection
Trial [26] before and after CPB. Both histological, alveolar cell, differential count of leucocytes,
and metabolites were investigated. Profound histological, cellular, and metabolic changes were
identified in the lung tissue and BALF after CPB in all patients, regardless of their treatment allocation.
While all patients presented increased inflammatory cells, metabolic acidosis, protease activity,
and oxidative stress in BALF, HTK patients seem to be more protected against severe acidosis, excessive
fatty acid oxidation, and inflammation following an ischemia-reperfusion period.
2. Materials and Methods
2.1. Study Population
The Pulmonary Protection Trial was conducted in accordance with the Declaration of Helsinki,
and approved by the Committees on Biomedical Research Ethics of The Capital Region of Denmark
(approved number: H-1-2012-024), the Danish Medicines Agency (approved number: 2012024017,
EudraCT number: 2011-006290-25, protocol code: 4141), and the Danish Data Protection Agency
(approval number: 2011-41-7051). The study was registered at ClinicalTrials.gov (NCT01614951) and
monitored by Copenhagen University Hospital Good Clinical Practice Unit. The rationale for and
design of the trial and the primary results have been published [26,33].
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In the original study, The Pulmonary Protection Trial [26], 90 patients scheduled for elective
coronary artery bypass grafting, aortic valve replacement or a combination of both procedures at
Rigshospitalet, Copenhagen University Hospital, Denmark were included. The BALF and lung
biopsy procedures was first added to the trial halfway due to the complexity of the trial and the
number of involved trialist did not allow us to add the extra procedures until that point. The current
study is therefore a sub-study of the original Pulmonary Protection Trial [26] including patients
from whom BALF (47 patients) and lung biopsy (25 patients) specimens were collected. All subjects
gave their informed consent for inclusion before they participated in the study. Inclusion criteria
were adults (≥18 years) with chronic obstructive pulmonary disease (COPD). Exclusion criteria were
individuals with previous heart or lung surgeries, previous thoracic radiation, left ventricular ejection
fraction <20%, tracheal intubation or medically treated pneumonia prior to surgery. Patients were
randomized to three groups with 30 patients in each; i.e., pulmonary artery perfusion with oxygenated
blood (‘oxygenated’), pulmonary artery perfusion with HTK (‘HTK’), and standard regimen with no
perfusion of the pulmonary artery (‘standard CPB’), respectively.
2.2. Bronchoalveolar Lavage Fluid
Bronchoalveolar lavage fluid (BALF) was performed in a sub-segment of the right middle
lobe following induction of anesthesia before surgery and again at skin closure from 47 out of the
90 patients (standard CPB, n = 19; oxygenated, n = 15; HTK group, n = 13) using standardized
procedure [34]. Lidocaine gel (20 mg/g) was applied to the tip of the bronchoscope before insertion
and samples were collected in a standardized fashion [34]. In brief, three successive 50 mL aliquots
of isotonic saline (at 37 ◦C) were instilled, each aspirated immediately with low negative suction
pressure (<100 cm H2O), and pooled into a sterile glass container on ice to obtain one BALF
specimen. Pooled non-filtered and non-centrifuged BALF was immediately used to enumerate the
total number of nucleated cells per mL of retrieved BALF on an automated hematology analyzer
(Sysmex XE-2100, Sysmex Corp., Kobe, Japan) and differential cell counts were performed manually
after cytocentrifugation (Cytospin 4 Cytocentrifuge, Thermo Fisher Scientific, Hvidovre, Denmark)
with subsequent May-Grunwald-Giemsa staining (Sysmex SP-1000i, Sysmex Europe GmbH, Hamburg,
Germany). Differential cell counting was performed for ~200 cells according to standard morphological
criteria by two independent hematology technicians and data is presented as cells per mL BALF.
Cytospin samples containing >20% smudge cells and/or artefacts were excluded from analysis; five
samples were excluded according to these criteria.
For metabolite analysis, pooled non-filtered BALF was centrifuged in tubes containing a carrier
protein (1% BSA in PBS) at 3500 rpm and 4 ◦C for 15 min and the supernatants were kept at −80 ◦C
until analyzed on a BRUKER AVIII-600 MHz nuclear magnetic resonance (NMR) spectroscopy
(BrukerBioSpin, Rheinstetten, Germany) equipped with a cryogenically cooled, triple-resonance
CPP-TCI probe.
BALF samples were thawed for 30 min at 4 ◦C and centrifuged for 5 min (4 ◦C, 12,100× g) to
remove cells. Aliquots of 500 µL of supernatant were mixed with 100 µL D2O phosphate buffer
(0.2 M Na2HPO4/NaH2PO4, pH = 7.4, in 99% 2H2O) to minimize variation in pH and to provide
a field-frequency lock. Throughout the whole procedure samples were kept on ice. The prepared
samples were transferred to a 5 mm NMR tube and spectra were recorded at a temperature of 298.1 K.
1H-NMR spectra were acquired using a T2-filtered one-dimensional Carr-Purcell-Meiboom-Gill
(CPMG) [35] pulse sequence with water suppression, as previously described [13,14]. Spectra
acquisition was controlled using the TopSpin 3.1 software (Bruker BioSpin, Germany).
2.3. Lung Biopsy
Two lung biopsies were harvested from 25 out of the 90 patients (standard CPB, n = 9; oxygenated,
n = 9; HTK group, n = 7) from either the middle lobe or lingual at initiation of CPB and again after
weaning from CPB. The tissue was fixed in 10% formaldehyde solution followed by embedding
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in paraffin, and 4 µm sections were stained with hematoxylin and eosin for light microscopy.
A histopathological score of acute lung injury was evaluated by a pathologist in accordance with
the Mikawa’s method [36]. The score graded each item on a 5-point scale (0, minimal damage;
1, mild damage; 2, moderate damage; 3, severe damage; 4, maximal damage) based on (a) congestion
in the alveolar capillaries, hemorrhage, (b) neutrophilic infiltration or aggregation in airspace or vessel
wall, (c) thickness of the alveolar septae, and (d) hyaline membrane formation [37,38].
2.4. Data Analysis
CPMG spectra were manually phased and baseline corrected, calibrated to the alanine doublet
at 1.48 ppm in TopSpin 3.1 and reduced to integrals of 0.001 ppm bin widths excluding the water
region (4.5–5.1 ppm) in the AMIX (Analysis of MIXtures v. 3.9.10, Bruker BioSpin, Karlsruhe, Germany)
software. The remaining spectral data was exported to MATLAB (R2016a, MathWork) and was
subsequently normalized to total sum of the spectral intensity, log transformed, and mean centered.
Multivariate unsupervised pattern recognition analysis was performed using the PLS Toolbox 6.5
(Eigenvector Research, Wenatchee, WA, USA). Unsupervised principal component analysis (PCA) was
carried out to identify possible outliers and trends in the data. Data was visualized by plotting the
scores of the first two principal components (PC1 and PC2). Loadings plot was used to identify the
significant spectral regions responsible for sample clustering in the scores plot.
Metabolites were assigned based on our previous study [14] and the Human Metabolite
Database [39] while metabolite quantification was determined using peak fitting option in the MNOVA
Mestrelab Research v.12 software. The statistical analysis was performed in the IBM® SPSS Statistics
software (v. 24, SPSS Inc., Armonk, NY, USA).
To be able to determine differences between lung histopathological score, differential cell
counts, and metabolites measured before and after surgery, we first employed a Shapiro-Wilk test
to verify if the data follows a normal distribution. Accordingly, pair t-test or the nonparametric test
Mann-Whitney-Wilcoxon was applied. Also, to detect differences between paired BALF samples
collected within the three groups before and after the surgery a factorial two-way analysis of variance
(ANOVA) with Tukey’s post-hoc or the Kruskal Wallis test was used for multiple comparisons. Overall
fold changes were calculated by comparing after versus before CPB values. Additionally, the effect
of treatment was assessed by calculating FC differences between oxygenated versus standard CPB
and HTK versus standard CPB groups from sample collected after CPB only. A calculated two-tailed
p-value of less than 0.05 was considered statistically significant. Bar plots with mean ± standard
deviation (SD) representing 95% confidence level was used to visualize the data.
3. Results
Of the 90 patients included in The Pulmonary Protection Trial, BALF was collected before and
after CPB in 47 patients and lung biopsies in 25 patients. Distribution to the lung protection and
standard regimens, patient characteristics, duration of surgery, and arterial oxygenation are provided
in Table 1. There was no statistic significant difference between the three groups of patients.
Table 1. Patient characteristics.
HTK/Oxygenated/Standard CPB
Patient no. BALF: 13/15/19 (Lung biopsy: 7/9/9)
Age-years (mean ± SD) 72 ± 9; 71 ± 12; 70 ± 8
Gender (male/female) 10/3; 12/3; 17/2
Cardiopulmonary bypass time, min. (mean ± SD) 96 ± 22; 104 ± 63; 107 ± 52
Aortic cross-clamp time, min. (mean ± SD) 61 ± 13; 57 ± 44; 67 ± 42
End-CPB PaO2/FiO2 (kPa) (mean ± SD) 29 ± 10; 32 ± 10; 27 ± 11
Abbreviation: BALF, bronchoalveolar lavage fluid; HTK, histidine-tryptophan-ketoglutarate; CPB, cardiopulmonary
bypass; SD, standard deviation; min., minutes; PaO2/FiO2, partial pressure of oxygen/fraction of inspired oxygen
ratio in kPa.
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3.1. Lung Histological and Cellular Changes during Surgery
Two lung tissue samples were obtained from 25 patients before and after CPB. Histopathological
tissue changes (Figure 1A) and slightly increases in the total acute lung injury scores (Table 2)
together with thickened alveolar sepae, alveolar congestion, and neutrophil infiltration were observed
postoperatively, irrespective of treatment allocation.
Two BALF samples were obtained from 47 patients before and after CPB. Figure 1B shows
representative image of the histological examination of BALF in one of the patients. Several different
nucleated cells (e.g., white blood cells including neutrophils, lymphocytes, and macrophages; other cells
including cilia) and non-nucleated cells (e.g., broken nucleated cells, smudge, cellular fragments, etc.)
were present in post-CPB samples, indicating increased permeability of the alveolar membrane with
cell influx from the blood stream initiated by an inflammatory response during surgery (Table 3).
No statistically significant difference was observed in the cellular levels across the three groups.
The picture that emerges from post-CPB BALF cellular count is one of inflammation with increased
total number of nucleated white blood cells, cilia and non-nucleated cells, and a decreased number
of macrophages and lymphocytes. A slightly increased number of neutrophils were observed
postoperatively; however, the change was statistically insignificant.
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Figure 1. Lung histologica (A) and BALF cellular (B) changes during surgery. (A) Image from a patient
before ( bove) and after CPB (below) presenting all possible outcomes n the 5-point lung i jury scale
(congestion in the alveolar capillaries, hemorrhage, neutrophilic infiltratio or aggregation in airspace or
vessel wall, thickness of the alveolar septae, and hyaline membrane formation). Additional information
about the lung injury score is provided in Section 4.3. (B) Representative image of a BALF sample
taken from a patient after CPB. The morphology of the most common cells identified is shown below.
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Table 2. Lung histopathological changes from before and after CPB.
Lung Tissue Groups
Before After Before vs. After Time-Group
Mean Min Max Mean Min Max p-Value p-Value
Alveolar congestion
Control 1.1 1 2 1.2 1 2
0.06 * 0.62HTK 1.0 1 1 1.3 1 2
O2 1.1 1 2 1.3 1 2
Heamorhage
Control 0.4 0 2 0.4 0 2
0.72 0.64HTK 0.1 0 1 0.3 0 1
O2 0.2 0 1 0.2 0 1
Neutrophilic infiltration
Control 1.1 1 2 1.6 1 2
<0.001 0.32HTK 1.1 1 2 1.5 1 2
O2 1.2 1 2 1.3 1 2
Thickness of alveolar wall
hyaline membranes
Control 1.4 1 3 1.6 1 3
0.01 * 0.58HTK 1.6 1 3 2.1 1 3
O2 1.5 1 3 1.6 1 3
Total score
Control 4.1 3 6 4.6 3 7
0.001 0.36HTK 3.7 3 5 5.1 3 7
O2 3.9 3 7 4.3 3 7
Pair t-test or its corresponding non-parametric test (*) was used to identified differences between paired samples
(Before vs. After CPB) and factorial two-way ANOVA to detect differences between patients as a consequence of
surgery and treatment received (Time-Group interaction). A p-value < 0.05 was considered significant. Data is
presented as means, minimum (min) and maximum (max) values.
Table 3. Results of BALF cellular count in samples collected before and after CPB.
BALF Cells Group
Before After Before vs. After Time-Group
Mean Min Max Mean Min Max p-Value p-Value
Total white blood cells
Control 157,435 22,000 990,000 239,777 52,000 1,020,000
0.015 * 0.59HTK 163,846 9000 401,000 173,615 48,000 415,000
O2 205,071 43,000 504,000 328,333 74,000 1,185,000
Neutrophils
Control 18.5 0 89 23.9 1 145
0.44 0.79HTK 20.1 2 79 19.5 2 110
O2 21.0 1 164 27.0 0 81
Lymphocytes
Control 7.9 1 25 4.1 0 18
0.007 * 0.78HTK 17.5 0 86 13.8 0 46
O2 10.9 0 54 10.1 0 50
Eosinocytes
Control 0.9 0 3 0.8 0 5
0.84 0.96HTK 0.9 0 3 0.9 0 6
O2 2.4 0 21 2.2 0 17
Macrophages
Control 161.2 3 274 119.7 12 225
0.02 * 0.26HTK 147.9 42 265 158.2 37 227
O2 170.4 12 216 135.5 10 217
Other cells including
cilia
Control 12.4 0 89 54.1 0 272
0003 * 0.19HTK 22.0 0 230 24.3 0 122
O2 5.1 0 41 30.9 0 176
Non-nucleated cells
including broken cells
and smudge
Control 58.4 3 471 98.1 2 293
0.05 * 0.63HTK 51.8 3 184 48.2 6 221
O2 36.9 1 278 65.7 2 200
Pair t-test or its corresponding non-parametric test (*) was used to identified differences between paired samples
(Before vs. After CPB) and factorial two-way ANOVA to detect differences between patients as a consequence of
surgery and treatment received (Time-Group interaction). A p-value < 0.05 was considered significant.
3.2. Lung Metabolite Profiles
Figure 2 illustrates a region of one-dimensional 1H-NMR spectra of BALF samples from one
patient, collected before (black) and after (grey) CPB. Visual inspection of both spectra revealed a larger
number of intensities in the post-CPB sample, indicating an increased number of metabolites.
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Figure 2. 600 MHz 1H-NMR CPMG spectra of metabolic intensities in one patient’s bronchoalveolar
lavage fluid obtained before (black) and after CPB (grey). The position of a signal is a characteristic of
a given compound, while the area under the signal is proportional to the compound’s concentration.
An increased number is observed in the signals of sample collected after CPB.
Unsupervised principal component analysis (PCA) revealed that the main variation in patients’
metabolite profiles is due to the ischemia-reperfusion itself (35%), as demonstrated by sample clustering
along the first principal component (PC1) (Figure 3A). The second main variation (15.7%) is due
to the treatment received during CPB (PC2); with HTK patients clustering separately compared
to the overlapping standard CPB and oxygenated blood groups. In order to avoid loss of valuable
information, metabolite changes related to both CPB and treatment regimens received will be presented
(Table 4). In general, similar metabolite trends were observed post-CPB in all patients irrespective of the
intervention. For example, 3 fold to 10 fold change (FC) increases were observed in the concentration
of metabolites involved in glycolysis (glucose, lactate, and pyruvate), while metabolites involved in the
urea cycle and nitric oxide (NO) production (urea, arginine, and methionine) were markedly elevated
in all patients with FC ≥ 20 times (p < 0.0001), indicating significant changes in these pathways
during CPB. For some metabolites, patients receiving either the standard regimen or pulmonary
perfusion with oxygenated blood appeared to have similar trends (Table 4 and Figure 3B). For example,
the NO inhibitor dimethylamine (DMA) was found to be elevated in all patients after CPB; however,
the standard regimen and pulmonary perfusion with oxygenated blood group presented less increases
compared to the HTK-receiving group (FC = 2.1, p = 0.004). Augmented levels of metabolites involved
in protein catabolism (alanine, valine, isoleucine, creatine, creatinine, and phenylalanine) were also
detected in all patients (FC ≥ 2, p ≤ 0.01), with highest alanine values in the HTK-receiving group.
Dimethyl sulfone, known to have anti-inflammatory activity, and the by-products of purine metabolism
hypoxanthine and inosine, known to be linked to oxidative stress formation, were also elevated in all
patients post-CPB. However, while no significant difference was observed in the levels of dimethyl
sulfone in the standard versus oxygenated blood groups post-CPB (FC = 0.9, p = 0.8, Figure 3C), patients
receiving HTK presented a 2.1 FC increase (p = 0.004) compared to the standard regimen. Finally,
some metabolites showed changes only in the standard and oxygenated group post-CPB, while their
levels remained unchanged in the HTK-receiving group or example, while glycerol concentration
increased in both the standard regimen and oxygenated blood groups following CPB (FC= 1.3, p = 0.7),
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glycerol values remained unchanged in the HTK group (p = 0.20). Similar trends were observed with
respect to acetoacetic acid (p = 0.37) and the TCA cycle metabolites 2-ketoglutarate (p = 0.51) and
succinate (p = 0.20) in the HTK-receiving patients, indicating a preservation of the molecular pathways
involved in the synthesis of these metabolites.
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marked (*) and further displayed in (C) with mean and 95% confidence intervals. TCA: tricarboxylic 
cycle acid; BCCA: branch chain amino acid. 
Figure 3. Lung metabolic profiles. (A) Principal component analysis (PCA) before (−PC1 axis) and after
CPB (+PC1 axis) colored by the treatment received (standard CPB, blue; oxygenated blood, red; HTK,
green). (B) Averaged heat-map representation of samples collected before (bottom raw) and after CPB
(second to forth raw). Data are normalized to total intensity and auto-scaled, colored coded according
to the levels of metabolites identified at a particularly time point and group; e.g., blue represent
lower concentrations of metabolites, while red represents metabolites in which concentration increased
post-CPB. Six metabolites presenting different trends across the groups are marked (*) and further
displayed in (C) with mean and 95% confidence intervals. TCA: tricarboxylic cycle acid; BCCA: branch
chain amino acid.
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Table 4. Metabolite profiles before and after CPB.
BALF Metabolites
Before CPB After CPB CPB Effect Treatment Effect
Control HTK O2 Control HTK O2 Time (After vs. Before) Time * Group HTK/Control O2/Control
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD FC p-Value p-Value FC p-Value FC p-Value
Glycerol 31.1 34 33.4 43 36.8 40 143.3 37 46.6 41 185.4 38 - - 0.11 0.3 0.029 1.3 0.7
Phosphocholine 7.7 7 5.1 9 8.0 8 18.6 7 14.5 8 37.0 8 2 <0.0001 0.7 0.9 0.6 2.2 0.3
N-Acetyl-Glucosamine 1.7 2 1.8 2 2.9 2 9.6 2 3.3 2 11.2 2 - - 0.05 0.3 0.013 1.1 0.8
Acetate 9.0 1 9.6 2 7.6 1 13.7 1 11.4 2 13.9 1 1.6 <0.0001 0.9 0.9 0.3 1 0.9
Acetoacetic acid 7.5 6 7.2 8 9.8 7 29.3 7 10.6 7 34.2 7 - - 0.14 0.3 0.027 1.1 0.8
Acetone 5.6 2 4.6 3 6.2 2 15.8 2 10.5 2 10.7 2 2 <0.0001 0.9 0.6 0.3 0.7 0.3
Glucose 8.8 9 12.1 12 11.1 11 83.4 10 66.3 11 71.9 11 10 <0.0001 1.0 0.9 0.7 0.9 0.7
Lactate 70.6 19 73.8 24 83.2 22 224.0 21 178.0 23 228.1 21 2.9 <0.0001 0.4 0.8 0.2 1 0.9
Pyruvate 0.9 1 1.4 1 1.9 1 7.6 1 7.3 1 7.5 1 6.2 <0.0001 1.0 1 1 1 0.9
Alanine 1.1 2 2.3 3 2.8 3 11.0 3 22.1 3 10.9 3 7.9 <0.0001 0.05 1.8 0.13 1 1
Citrate 1.9 1 3.8 1 4.6 1 9.6 1 7.3 1 9.7 1 2.4 <0.0001 0.7 0.8 0.3 1.1 0.8
2-Ketoglutarate 12.3 5 14.0 6 13.9 6 33.9 6 16.0 6 38.1 6 - - 0.02 0.5 0.005 1.1 0.8
Succinate 4.0 3 5.1 4 5.5 3 16.9 3 7.5 3 19.5 3 - - 0.08 0.4 0.025 1.1 0.8
Creatine 0.4 1 0.7 1 0.6 1 3.0 1 3.0 1 3.6 1 5.8 <0.0001 0.7 1 1 1.2 0.7
Creatinine 2.3 2 1.8 2 3.5 2 18.8 2 14.9 2 15.5 2 6.5 <0.0001 0.8 0.8 0.5 0.8 0.5
Isoleucine 1.1 1 1.4 1 0.8 1 3.9 1 3.3 1 2.3 1 2.3 0.0004 0.3 0.9 0.4 0.7 0.2
Valine 1.6 1 2.1 1 1.9 1 5.1 1 5.1 1 3.5 1 2.2 0.0001 0.07 0.9 0.7 0.7 0.2
Urea 8.8 6 4.3 8 7.2 7 39.5 7 44.2 7 47.2 7 19.9 <0.0001 0.6 1.4 0.3 1.2 0.4
Arginine 2.7 11 2.2 14 2.8 13 74.6 12 50.2 14 69.3 13 28.1 <0.0001 0.5 0.7 0.5 1 0.9
Methionine 0.2 3 0.0 3 0.0 3 13.2 3 12.5 3 12.7 3 88.6 <0.0001 1.0 1.1 0.8 1 1
Dimethylamine 0.4 0 0.6 0 0.3 0 1.7 0 2.0 0 1.1 0 3.3 <0.0001 0.14 1.2 0.5 0.6 0.2
Dimethyl sulfone 3.3 1 3.9 1 4.1 1 6.0 1 11.7 1 5.4 1 - - 0.004 2.1 0.004 0.9 0.8
Histidine 0.1 29 0.0 36 0.5 33 3.0 31 250.8 35 3.2 32 - - <0.0001 67.8 0.0002 1.1 0.9
Phenylalanine 22.8 4 18.2 6 23.7 5 36.0 5 26.8 5 34.1 5 2 0.01 0.3 0.7 0.14 0.9 0.5
Inosine 4.5 1 4.2 1 3.4 1 5.1 1 6.2 1 4.9 1 1.3 0.008 0.5 1.2 0.4 0.9 0.5
Hypoxanthine 4.6 1 4.4 2 4.4 2 9.0 1 10.4 2 9.6 1 3.3 0.0002 0.9 1.1 0.7 1 1
Mannitol 0.0 0 0.0 0 0.0 0 687.7 69 675.4 76 624.8 71 90 <0.0001 0.9 1 1 0.9 0.6
Because several metabolites were without any signal in samples collected before CPB, their mean concentrations were below the limit of NMR detection. Mean fold change (FC) were
calculated as the ratio between the metabolites measured (1) before and after CPB (CPB effect), and (2) by comparing the standard regimen versus oxygenated blood group and the
standard CPB regimen versus HTK group after CPB (Treatment effect). “-” these metabolites have been found different among groups post-CPB, and hence, FC and p-values for the before
and after analysis are not provided to avoid misinterpretation. To assess the effect of CPB on BALF metabolites the pair t-test or its corresponding non-parametric test was applied, while
for the effect of treatment received the factorial two-way ANOVA (Time-Group interactions) and its corresponding Tuckey’s post-hoc test for group comparison was used (HTK/Control;
O2/Control). A two-tailed p-value ≤ 0.05 was considered significant.
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4. Discussion
Lung injury following cardiac surgeries with CPB is a common and potentially serious event that
may lead to ARDS [5–8]. Although various factors have been found to influence the onset of lung injury
and the progression into hypoxemic respiratory failure, the associated molecular alterations remain
poorly characterized. In this study, we have characterized lung morphological, cellular, and metabolic
changes following ischemia-reperfusion. These findings may add new insights into the molecular
mechanism of lung injury during CPB and may play a key role in understanding the progression
towards respiratory failure, thus enabling development of potential treatment modalities.
4.1. Lung Histological and Cellular Changes during Surgery
It has previously been shown in animal models that CPB is directly linked to vascular permeability
and alveolar flooding [27,40]. In 1967 Tilney and co-workers [41] performed histological examination
of lung tissue from deceased patients following prolonged CPB and found hypercellular and thickened
alveolar septae, fresh hemorrhage, and edema within alveoli with prominent hyaline membranes.
In 1972 these changes were also found in patients surviving cardiac surgery [42]. Our results
confirm the histopathological evidence of acute lung injury immediately after CPB, with alveolar
congestion, neutrophilic infiltration, and thickened alveolar septae in all patients regardless of the
treatment received.
The observed increase in alveolar cellularity confirmed the trans-endothelial migration of
inflammatory cells following surgery. Only a few human studies have described cellular changes in
BALF following CPB. Frass and colleagues [43] found no significant changes in BALF differential cell
count while Marsh’s group [44] found a peak in cellularity on day two. This was mainly driven by
an increase in neutrophils associated with a corresponding fall in macrophages. Zhang and co-workers
found increased neutrophil concentration in BALF peaking at 12 h post-CPB [45], thus explaining why
the neutrophil count was unchanged two hours after CPB in our study.
4.2. Lung Metabolite Profiles
Overall, the metabonomics analysis revealed changes in the levels of metabolites involved in
energy metabolism, protein catabolism, lipids, purines, and polyamine metabolism. Compared with
morphological and cellular events, some metabolites showed significant differences between patients
receiving pulmonary perfusion with HTK compared to no pulmonary perfusion during CPB.
We found that metabolites involved in glycolysis were elevated in all patients after CPB.
Interestingly, lactate was similarly increased in all patients and this was especially noteworthy in
the patients receiving oxygenation blood perfusion, where a less hypoxic environment in the lungs
was expected. In addition, elevated levels of acetate were identified in all patients. Abnormal BALF
lactate [46] and acetate [47] levels have previously been linked to the activation of inflammatory
cells during lung injury; hence, our findings indicate increased anaerobic metabolite concentrations
(lactate and acetate) and inflammation (BALF cellularity) in all patients during ischemia-reperfusion
injury. An interesting finding is that the levels of acetoacetic acid were only elevated in the oxygenated
and standard CPB patients after surgery. Acetoacetic acid is known to be produced from acetyl-CoA
by breakdown of fatty acids and complex lipids. Our data shows that the levels of the components of
cellular membranes, phosphocholine and glycerol were augmented after CPB in the oxygenated group
and in the standard group, but not in the HTK group. Hence, the results indicate that HTK patients
were protected from excessive fatty acid oxidation in comparison to the other groups. Our results are
supported by the systematic review performed by Edelman and co-workers [48], where tryptophan
in the HTK solution was described as stabilizing cell membranes while histidine buffers the ongoing
metabolic acidosis during ischemia.
Several amino acids were found to be highly elevated at the end of surgery in all patients.
Free amino acids in BALF samples have been previously linked to increased protease activity
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in the alveoli [49,50] and lung injury [47], hence our results might indicate the presence of
ischemia-reperfusion injury during CPB in all patients.
The by-products of purine metabolism, hypoxanthine and inosine, were also found to be
elevated at the end of surgery. These metabolites are known to accumulate during ischemia due
to reduced oxygen and energy supply. Hypoxanthine has been previously found to be elevated in
ARDS patients and its presence in the alveoli has been linked to the generation of alveolar oxygen
superoxide and hence, of oxidative stress [51,52]. Our findings suggest increased oxidative stress
during surgery, with no differences between the three groups. It is well known that reduced oxygen
concentrations in the lung enhance the activity of polyamine metabolism [53]. When compared
with preoperative concentrations, the polyamine metabolites methionine and arginine were found
in excess. Normal epithelial cells synthesize polyamines and the lungs are in fact endowed with
a much higher polyamine uptake system than other organs, in order to protect the tissue against
oxidative stress [53]; however, such excesses (FC > 20) may suggest toxic reactions of the cells and
their surroundings. Excess polyamine metabolites were previously found to induce disruption of
the barrier function of the epithelium, and lead to pulmonary edema with subsequent invasion of
inflammatory cells [53]. Hence, our data might reflect increased oxidative stress and a possible
cellular disruption, facilitating molecular leakage into the alveolar space, regardless of the pulmonary
artery perfusion strategy used. Apart from being involved in polyamine synthesis, arginine is at
a crossroad for multiple other pathways and it is a common substrate for arginase and nitric oxygen
species via urea cycle. Urea was also found elevated (19.9-fold), indicating an increased arginase
activity. Dimethylamine, a potent inhibitor of NO synthesis [54] was found to be increased 3.3-fold.
Its increases might indicate accumulation of reactive oxygen and nitrogen species, contributing to lung
tissue damage in all patients.
In line with higher oxidative stress, the keto acid of the TCA cycle metabolite 2-ketoglutaric acid
and its converted metabolic form, succinate, were found to be elevated in the oxygenated and standard
CPB patients, but not in the HTK group after ischemia-reperfusion. 2-Ketoglutaric acid has a role in
detoxification of reactive oxygen species (ROS) [55] and it is known to improve ATP production during
reperfusion [41]. Increased levels of these metabolites in standard and oxygenated patients might
indicate that they are being synthesized to balance the oxidant-antioxidant defense in these patients.
Since HTK contains 2-ketoglutaric acid [27], a plausible explanation for its insignificant increase
among HTK patients might be that the cardioplegia provided the necessary amount of protection.
Finally, dimethyl sulfone, a metabolite with anti-inflammatory activity, was found to be elevated
after ischemia-reperfusion in all patients. Because the HTK patients presented a 2.1-fold increase in
its levels compared to the standard CPB group, it might possibly indicate that HTK provides some
protection against the activity of inflammatory cells. These findings are in line with the study by
Warnecke et al. [29] where piglets’ lungs were perfused with three different preservation solutions
followed by BALF, with the lowest post-perfusion cell count in the piglets receiving HTK solution.
4.3. Strengths and Limitations
Although this study is the first of its kind, there are some limitations to acknowledge. Firstly, in this
sub-study of the original Pulmonary Protection Trial [26], only a limited number of the 90 patients
have contributed to the present results; 47 patients with BALF and 25 of these patients with lung
biopsies. Selection of patients was based on organizational logistics and not patient characteristics.
Another limitation is the use of a semi-quantitative grading system to obtain the histopathological
scores of tissue damage. Quantitative stereological analysis by the use of more robust unbiased
morphometry might improve the results, but this would require a different and more elaborate
study design regarding tissue sampling and evaluation, which is difficult to apply in a clinical study.
In addition, since the BALF samples have been diluted with isotonic saline before their collection,
important information from low concentration metabolites may be missing. Also, lidocaine has been
used during the BALF procedure. Spectroscopically, lidocaine peaks spanned several metabolite-rich
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spectral regions, and hence, the number of detected metabolites was reduced, resulting in possible loss
of valuable information. In addition, mannitol peaks were also overlapping metabolites, especially in
the 4–3 ppm region, hence several metabolites were unable to be detected and quantified.
5. Conclusions
In this sub-study of The Pulmonary Protection Trial we found molecular and histological changes
in the lung tissue and BALF following CPB with slight alveolar congestion, thickened alveolar septae,
neutrophilic infiltration, increased BALF inflammatory cells, metabolic acidosis, increased protease
activity, and oxidative stress. Pulmonary perfusion with HTK during CPB seemed to protect against
severe acidosis, excessive fatty acid oxidation, and inflammation during lung ischemia-reperfusion
injury. Additional studies are needed to confirm the results and to further elucidate the deranged
mechanisms involved in the progression to ARDS.
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